Статья
К 125-ЛЕТИЮ АЦЕТИЛСАЛИЦИЛОВОЙ КИСЛОТЫ
Освещается опыт клинического применения ацетилсалициловой кислоты (АСК) с момента ее синтеза в 1887 г. Рассматриваются особенности механизма действия и место АСК среди современных антитромбоцитарных средств. Приводится доказательная база клинического применения АСК, а также обсуждается проблема резистентности к антитромбоци-тарной терапии. Рассматривают особенности взаимодействия различных препаратов с АСК и её плейотропные эффекты.
1. Rosamond W., Flegal K., Furie K. et al. Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117(4):e25-146.
2. Gawaz M., editor. Blood platelets — clinical relevance. Stuttgart: Georg Thieme Verlag; 2010.
3. Gershlick A.H. Antiplatelet therapy. Hosp Med 2000;61: р15-23
4. Schror K. Antiplatelets drugs. A comparative review. Drugs 1995; 50: р 7-28.
5. PatronoC., Rocca B. Aspirin, 110 years later. J Thromb Haemost 2009; 7 (Suppl. 1): 258-61.
6. Patrono C., Baigent C., Hirsh J., Roth G. Аntiplatelet Drugs. Chest 2008;133 (6 suppl):199S-233S.
7. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-1294.
8. Schror K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treat¬ment andprophylaxis. Semin Thromb Hemost 1997;23: 349-356.
9. Schror K. The effect of prostaglandins and thromboxane A2 on coronary vessel tone—mechanisms of action and therapeutic implications. Eur Heart J 1993; 14 Suppl: 34-41.
10. Pedersen A., FitzGerald G. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984;311:1206–1211.
11. Antithrombotic Trials Collaboration. Prevantion of death, myocardial infarction and stroke by antiplatelet therapy in high-risk patients. BMJ 2002; 324: 71-86.
12. Antithrombotic Trialists Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta–analysis of individual participant data from randomized trials. Lancet 2009; 373: 1849–1860.
13. U.S. Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force. Recommendation statement. Ann Intern Med 2009; 150 (6): 396–404.
14. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106(3):388-91.
15. Buse J.B., Ginsberg H.N., Bakris G.L. et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007;115(1):114-26.
16. Algra A., Greving J.P. Aspirin in primary prevention: sex and baseline risk matter. Lancet 2009; 373: 1821–22.
17. Lindemann S., Tolley N., Dixon D. et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001;154:485-490
18. Weil J., Colin-Jones D., Langman M. et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827-830.
19. Yeomans N.D., Lanas A.I., Talley N.J. et al. Prevalence and incidence of gas-troduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005;22:795-801.
20. Abraham N.S., Hartman C., Castillo D. et al. Effectiveness of national provider prescription of PPI gastroprotection among elderly NSAID users. Am J Gas-troenterol 2008;103:323-332.
21. Hall D. The aspirin-angiotensin-converting enzyme inhibitor tradeoff: to halve and halve not. J Am Coll Cardiol 2000; 35: 1808-1812.
22. Bhatt D.L., Scheiman J., Abraham N.S. et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008;52(18):1502-17.
23. Muller I., Seyfarth M., Rudiger S. et al. Effect of a high loading dose of Clopidogrel on platelet function in patients undergoing coronary stent place¬ment. Heart 2001; 85: 92-93.
24. Gum P.A., Kottke-Marchant K., Poggio E.D. et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001:88:230-235.
25. Buchanan M.R., Brister S.J. Individual variation in the effects of ASA on platelet function: implica¬tions for the use of ASA clinically. Can J Cardiol 1995:11: 221-227
26. Cotter G., Shemesh E., Zehavi M. et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J 2004; 147: 293-300.
27. Schwartz K.A., Schwartz D.E., Ghosheh K. et al. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005; 95: 973-975.
28. Catella-Lawson F., Reilly M.P., Kapoor S.C. et al. Cyclo-oxygenase inhibitors and the antiplatelet effects ofaspirin. N Engl J Med 2001;345: 1809-1817.
29. Borna C., Lazarowski E., van Heusden C. et al. Resistance to aspirin is increased by ST-elevation myo-cardial infarction and correlates with adenosine diphosphate levels. Thromb J 2005; 3: 10.
30. Fateh-Moghadam S., Plockinger U., Cabeza N. et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 2005; 42: 99-103.
31. Maree A.O., Curtin R.J., Chubb A. et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thrombos Haemostas 2005;3:2340–2345.
32. Cox D., Maree A.O., Dooley M. et al. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006;37:8:2153-2158.
33. Santoso S., Kunicki T.J., Kroll H. et al. Association of the platelet glycoprotein la C807T gene polymorphism with nonfatal myocardial infarction in younger patients. Blood 1999; 93: 2449-2253.
34. Gonzalez-Conejero R., Lozano M.L., Rivera J. et al. Polymorphisms of platelet membrane glycopro-tein Ib associated with arterial thrombotic disease. Blood 1998; 92(8): 2771-2776.
35. Carlsson L.E., Greinacher A., Spitzer C. et al. Polymorphisms of the human platelet antigens HPA-1, HPA-2, HPA-3, and HPA-5 on the platelet receptors for fib-rinogen (GPIIb/IIIa), von Willebrand factor (GPIb/IX), and collagen (GPIa/IIa) are not correlated with an increased risk for stroke. Stroke 1997; 28(7): 1392-1395.
36. Ardissino D., Mannucci P.M., Merlini P.A. et al. Pro-thrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999; 94(1): 46-51.
37. Ollikainen E., Mikkelsson J., Perola M. et al. Platelet membrane collagen receptor glycoprotein VI polymorphism is associated with coronary thrombosis and fatal myocardial infarction in middle-aged men. Atherosclerosis 2004; 176: 95-99.
38. Bray P.F., Howard T.D., Vittinghoff E. et al. Effect of genetic variations in platelet glycoproteins Ibal-pha and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy. Blood 2007; 109(5): 1862-1869.
39. Yu Z.Q., Dong N.Z., Gao W.Q. et al. Study on T13254C polymorphism of the platelet membrane glycoprotein VI in Chinese Han population. Zhonghua Xue Ye Xue Za Zhi 2005; 26(3): 140-143.
40. Fontana P., Gaussem P., Aiach M. et al. P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation 2003; 108: 2971-2973.
41. Hetherington S.L., Singh R.K., Lodwick D. et al. Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP. Arterioscler Thromb Vase Biol 2005; 251(1): 252-257.
42. Li Q., Chen B.L., Ozdemir V. et al. Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Pharmacogenomics 2007; 8(6): 577-586.
43. Evans W.E., McLeod H.L. Pharmacogenomics—drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-549.
44. Maree A.O., Curtin R.J., Chubb A. et al. Cyclooxyge-nase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005; 3: 2340-2345.
45. Lepantalo A., Mikkelsson J., Resendiz J.C. et al. Polymorphisms of COX-1 and GPV1 associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 2006; 95: 253-259.
46. Gonzalez-Conejero R., Rivera J., Corral J. et al. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 2005; 36: 276-280.
47. Matsubara Y., Murata M., Maruyama T. et al. Association between diabetic retinopathy and genetic variations in alpha2betal integrin, a platelet receptor for collagen. Blood 2000; 95: 1560-1564.
48. Leor J., Reicher-Reiss H., Goldbourt U. et al. Aspirin and mortality in patients treated with angioten-sin-converting enzyme inhibitors: a cohort study of 11,575 patients with coronary artery disease. J Am Coll Cardiol 1999; 33: 1920-1925.
49. Hall D. The aspirin-angiotensin-converting enzyme inhibitor tradeoff: to halve and halve not. J Am Coll Cardiol 2000; 35: 1808-1812.
50. Cleland J.G., Bulpitt C.J., Falk R.H. et al. Is aspirin safe for patients with heart failure? Br Heart J 1995; 74:215-219.
51. Strand V. Are COX-2 Inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with the risk of cardiovascular events taking low-dose aspirin? Lancet 2007; 370 (9605): 2138-2151.
52. Singh G., Graham D., Wang H. et al. Concomitant aspirin use reduces the risk of acute myocardial infarction in users of cycloocygenase-2 selective and some non-selective nonsteroidal anti-inflammatory drugs. Ann Rheum Dis 2006; 65: 61.
53. Catella-Lawson F., Reilly M.P., Kapoor S.C. et al. Cyclo-oxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-1817.
54. Rothwell P.M., Wilson M., Elwin C.E. et al. Long-term effect of aspirin on col-orectal cancer incidence and mortality: 20-year follow-up of five randomized trials. Lancet 2010;376(9754):1741-50.
55. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg 2010;38 Suppl:S1-S52.